<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899713</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL21_0552</org_study_id>
    <nct_id>NCT04899713</nct_id>
  </id_info>
  <brief_title>NEOZOL_Follow-up Study</brief_title>
  <acronym>NEOZOL_FU</acronym>
  <official_title>Long-term Survival of Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy With or Without Zoledronic Acid (ZOMETA®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer is the most common cancer in women and is the leading cause of death from&#xD;
      cancer in France.&#xD;
&#xD;
      The main types of treatment used to treat breast cancer are surgery, chemotherapy,&#xD;
      radiotherapy, hormone therapy and targeted therapies. In locally advanced breast cancer, a&#xD;
      neo-adjuvant chemotherapy treatment is currently recommended as it may provide a sufficient&#xD;
      tumour response to allow for conservative breast treatment.&#xD;
&#xD;
      Zoledronic acid (ZOL) is an N-biphosphonate used in the prevention of bone complications and&#xD;
      in the treatment of hypercalcaemia In vitro and in vivo studies have shown an effect of ZOL&#xD;
      on tumour and endothelial cells, supporting an anti-tumour activity of N-biphosphonates.&#xD;
&#xD;
      Between April 2010 and October 2013, 50 patients with locally advanced breast cancer were&#xD;
      randomized in the NEOZOL study to receive neoadjuvant chemotherapy with (n=26) or without&#xD;
      (n=24) zoledronic acid (ClinicalTrials.gov Identifier: NCT01367288). The primary objective of&#xD;
      this study was to evaluate the effect of the addition of ZOMETA® to neoadjuvant chemotherapy&#xD;
      on the change in serum VEGF concentration before and after neoadjuvant treatment (i.e. at the&#xD;
      time of surgery).&#xD;
&#xD;
      Assessment of long-term survival was not planned in the NEOZOL study protocol. The objective&#xD;
      of NEOZOL_FU study is to evaluate the survival of patients included in the NEOZOL study, 7&#xD;
      years after inclusion of the last patient.&#xD;
&#xD;
      This study will provide essential data on the long-term survival and risk of relapse of&#xD;
      patients with locally advanced breast cancer who have received neo-adjuvant chemotherapy with&#xD;
      or without zoledronic acid (ZOMETA®).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>31/12/2019</time_frame>
    <description>Event-free survival is defined as the time between the date of randomization and the date of the 1st event among: 1st documented locoregional or metastatic infiltrating relapse (not including in situ relapses) or death from whatever cause.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Locally Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental group (neo-adjuvant chemotherapy combined with ZOMETA®) (zoledronic acid)</arm_group_label>
    <description>Patients treated every 3 weeks (+/- 2 days ) for 8 cycles in total. The 4 first cycles : zoledronic acid 4 mg (in a 15 min. infusion) + doxorubicin (60 mg/m²) + cyclophosphamide (600 mg/m²). The 4 last cycles with zoledronic acid 4 mg (in a 15 min. infusion) + docetaxel (100 mg/m²)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (neo-adjuvant chemotherapy alone)</arm_group_label>
    <description>Patients treated every 3 weeks (+/- 2 days) for 8 cycles in total. The 4 first cycles : doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²). The 4 last cycles with docetaxel (100 mg/m²)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survival survey</intervention_name>
    <description>To assess the effect of adding ZOMETA® to neoadjuvant chemotherapy on event-free survival.</description>
    <arm_group_label>Control group (neo-adjuvant chemotherapy alone)</arm_group_label>
    <arm_group_label>Experimental group (neo-adjuvant chemotherapy combined with ZOMETA®) (zoledronic acid)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of 50 patients with locally advanced breast cancer (TNM IIa&#xD;
        or IIb or IIIa, tumor &gt; 2 cm, ductal or lobular histology), who benefited from neoadjuvant&#xD;
        chemotherapy associated ( n = 26) or not (n = 24) with the zoledronic acid, and having&#xD;
        participated in the NEOZOL study (NCT01367288)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Woman who signed a written consent, included and randomised in the main analysis of&#xD;
             the NEOZOL study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient's opposition to the use of her data in this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>MATHEVET, MD</last_name>
    <phone>795 567 520</phone>
    <phone_ext>+41</phone_ext>
    <email>Patrice.Mathevet@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FEBVEY-COMBES, MD</last_name>
    <phone>472 115 162</phone>
    <phone_ext>+33</phone_ext>
    <email>olivia.febvey-combes@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre hospitalier de Bourg en Bresse, Hôpital Fleyriat, Service d'Onco-Hématologie et de Gynécologie Obstétrique</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>LAMBERT, MD</last_name>
      <phone>474 454 647</phone>
      <phone_ext>+33</phone_ext>
      <email>jrlambert@ch-bourg01.fr</email>
    </contact>
    <contact_backup>
      <last_name>ORFEUVRE, MD</last_name>
      <phone>474 454 647</phone>
      <phone_ext>+33</phone_ext>
      <email>horfeuvre@ch-bourg01.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme Mère Enfant, Groupement Hospitalier EST, Service de Gynécologie Clinique</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>LE BAIL-CARVAL, MD</last_name>
      <phone>427 855 353</phone>
      <phone_ext>+33</phone_ext>
      <email>muriel.doret-dion@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer - Institut Jean Perrin, Service de Médecine Oncologique</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>MOURET-REYNIER, MD</last_name>
      <phone>473 278 080</phone>
      <phone_ext>+33</phone_ext>
      <email>marie-ange.mouret-reynier@cjp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Alpes Léman, Service de Gynécologie</name>
      <address>
        <city>Contamine-sur-Arve</city>
        <zip>74130</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>GIRARD, MD</last_name>
      <phone>450 822 000</phone>
      <phone_ext>+33</phone_ext>
      <email>sgirard@ch-alpes-leman.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Limoges, Hôpital Dupuytren 1, Service d'Oncologie Médicale,</name>
      <address>
        <city>Limoges</city>
        <zip>87022</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>TUBANIA-MATHIEU, MD</last_name>
      <phone>555 055 555</phone>
      <phone_ext>+33</phone_ext>
      <email>nicole.tubiana-mathieu@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard, Département de Cancérologie Médicale</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>RAY-COQUARD, MD</last_name>
      <phone>478 782 888</phone>
      <phone_ext>+33</phone_ext>
      <email>isabelle.ray-coquard@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen, Service d'Oncologie</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>DALIVOUST, MD</last_name>
      <phone>491 833 838</phone>
      <phone_ext>+33</phone_ext>
      <email>philippedalivoust@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montpellier - Hôpital St Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>TOPART, MD</last_name>
      <phone>467 330 176</phone>
      <phone_ext>+33</phone_ext>
      <email>d-topart@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <email>pl-giacalone@chu-montpellier.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Poitiers, Hôpital la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>FRITEL, MD</last_name>
      <phone>549 444 444</phone>
      <phone_ext>+33</phone_ext>
      <email>xavier.fritel@chu-poitiers.fr</email>
    </contact>
    <contact_backup>
      <last_name>RABAN, MD</last_name>
      <phone>549 444 444</phone>
      <phone_ext>+33</phone_ext>
      <email>nadia.raban@chu-poitiers.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>CHAULEUR, MD</last_name>
      <phone>477 917 000</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <contact_backup>
      <last_name>JACQUIN, MD</last_name>
      <phone>477 917 000</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-philippe.jacquin@icloire.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Thonon Hôpitaux du Léman, site Georges Pianta Service de Gynécologie Obstétrique</name>
      <address>
        <city>Thonon-les-Bains</city>
        <zip>74203</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>DELPIANO, MD</last_name>
      <phone>450 832 000</phone>
      <phone_ext>+33</phone_ext>
      <email>f-delpiano@ch-hopitauxduleman.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Zometa®</keyword>
  <keyword>Survival survey</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

